The Globe and Mail reports in its Wednesday, Sept. 13, edition that Echelon Partners analyst Stefan Quenneville has reaffirmed Quipt Home Medical as his "top pick," touting a "compelling" valuation. The Globe's David Leeder writes that Mr. Quenneville continues to target the shares at $11.75. Analysts on average target the shares at $13.76. Mr. Quenneville likes Quipt Home Medical's acquisition of a business with operations in Mississippi, Texas and Louisiana. Quipt announced the deal with an undisclosed party on Monday for 10 locations across the three states that report unaudited annual revenues of approximately $9-million (U.S.) with anticipated adjusted earnings before interest, taxes, depreciation and amortization of $2-million (U.S.) post integration. Mr. Quenneville says in a note: "While the price paid was not disclosed, presumably for competitive reasons, management highlighted that it was in-line with historical multiples it has paid for tuck-in acquisitions. ... Quipt continues to demonstrate that it remains in an M&A sweet spot, with ample opportunities to build regional scale in attractive markets. ... We continue to view QIPT as a compelling opportunity for longer-term investors."